Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (January 2017)
17 slides from Glaukos's investor presentation, Jan 10, 2017
Slide 1: January 2017
January 2017
Slide 2: Disclaimer
2 DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basi
Slide 3: Transforming glaucoma therapy
3 is transforming glaucoma therapy LARGE MARKET Growing $5bn global opportunity1 UNMET NEED Significant drawbacks of current treatments DEMONSTRATED EXECUTION Broad reimbursement and highly successful launch JUST THE BEGINNING Advanced portfolio of micro-scale injectable therapies 1 Market Scope est
Slide 4: 2016 Major Accomplishments
1. Reported 58% YoY global net sales growth through 9/30/16; exceeded U.S. surgeon training targets 2. Delivered 13 consecutive quarters of > 40% YoY growth since U.S. commercialization 3. Achieved gross margin in mid-80% range through 9/30/16 4 Added Anthem and Tricare to reach 95+% U.S. reimbursem
Slide 5: US Glaucoma Population
US GLAUCOMA POPULATION1 Reducing IOP is the only proven treatment for glaucoma Aging Population Drives Glaucoma Prevalence 1 Market Scope estimates for glaucoma prevalence; excludes ocular hypertension, Sept. 2016 2 Market Scope estimates for total global glaucoma market, Sept. 2016 Typically associ
Slide 6: How The Eye's Drainage System Works
6 How The Eye’s Drainage System Works Elevated IOP occurs when aqueous humor outflow through the trabecular meshwork and into Schlemm’s canal is reduced due to degeneration and obstruction Secondary outflow pathway is the suprachoroidal space
Slide 7: iStent vs. Conventional Surgery
7 Conventional Surgery iStent® vs. Conventional Surgery
Slide 8: Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy
8 Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy RESTORE FLOW FURTHER ENHANCE FLOW COMBINATION DRUG & FLOW iStent Inject, iStent Supra and iDose are not approved by the FDA. iStent Inject and iStent Supra are currently being evaluated in IDE clinical trials; iDose i
Slide 9: Compelling Clinical Results: Single iStent + Cataract Surgery Through 3 Years
9 Compelling Clinical Results: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through 3 Years Consecutive series of 62 eyes; decision to implant based on patient desire to reduce topical meds and intent to offer surgical treatment with favorable safety profile In consistent cohort of 39 eyes f
Slide 10: Compelling Clinical Results: US Retrospective Studies of Single iStent
10 Compelling Clinical Results: US Retrospective Studies of Single iStent + Cataract Surgery A consistent cohort of 107 open-angle glaucoma eyes followed through 2 years achieved mean IOP reduction of 22%, and 56% reduction in mean medications to 0.6 meds Study represents the largest sample size pub
Slide 11: Compelling Clinical Results: International Study of 1, 2 and 3 iStents
11 Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Prospective, randomized study of 119 OAG patients with preoperative unmedicated IOP of 22-38 mm Hg Safety data similar across all stent groups Demonstrates potential to titrate treatment based on
Slide 12: Clinical Research Program Statistics
18 12 Prospective clinical trials currently underway Clinical Research Program Statistics 55 Articles published in peer-reviewed journals
Slide 13: Q3 2016 Financial & Operational Performance
13 TOTAL NET SALES (in millions) Q3 2016 Financial & Operational Performance: Growth Reflects iStent Adoption Trends 13th consecutive quarter of at least 40% year-over-year growth in net sales Includes 189% growth in international sales, compared to Q3 2015 Reflects increased unit volume worldwide,
Slide 14: Current & Future Potential MIGS Market Participants
14 Current & Future Potential MIGS Market Participants ALCON cypass 6.35mm suprachoroidal device for implantation into supraciliary space using guidewire delivery (actual) Ivantis hydrus 8mm nitinol scaffolding device implanted into Schlemm’s canal (image) Allergan XEN (for Refractory glaucoma) 5mm
Slide 15: Financial Summary
15 Strong net sales growth, driven by increases in trained doctors and same-store sales Financial Summary $20.9 $45.6 $71.7 NET SALES (IN MILLIONS) $81.2 (9 mos) Nine months ended Sept 30 GROSS MARGIN 82% 86%* Ability to leverage efficient manufacturing and cost structure Continued investments in pi
Slide 16: Growth Strategies: Establishing MIGS as OAG Standard of Care
16 Increase US iStent adoption with seasoned sales force, broad reimbursement coverage and compelling clinical results Growth Strategies: Establishing MIGS as OAG Standard of Care 01 Secure FDA approvals with expanded indications for iStent pipeline products 02 Develop, secure regulatory approval fo
Slide 17: 17
17